NEW YORK (360Dx) – Indivumed and Flagship Biosciences today announced a partnership to expand their tissue-based biomarker development capabilities and clinical services to support advanced oncology diagnostics.
Under the terms of the agreement, the companies will offer services that combine Flagship’s experience in biomarker development and Indivumed’s multiplex immunohistochemistry assay development capabilities.
Financial and other terms of the agreement were not disclosed.
Westminster, Colorado-based Flagship and Hamburg, Germany-based Indivumed said that they share a goal to help accelerate the development and deployment of new treatment and diagnostic tools, and that they will explore options to expand cooperation toward that goal. The firms said they anticipate the client base of Indivumed will benefit from Flagship’s artificial intelligence-enabled computational tissue analysis digital pathology platform, which provides complimentary and comprehensive tissue profiling.
The joint initiative will also expand Indivumed’s portfolio of services by providing CAP-accredited and CLIA-certified testing capabilities.
Hartmut Juhl, CEO of Indivumed, said in a statement that Flagship's CAP-CLIA environment complements its testing facilities in Hamburg. Both companies are engaged in artificial intelligence and machine learning projects, opening prospects for future collaboration, he said.